Imagine there was a technology that could have saved the lives of everyone who died in the Japanese earthquake and tsunami and the Christchurch earthquake, with spare capacity for the Queensland floods. How much would you want the government to pay for that? Quite a lot, I’m guessing.
Of course that’s impossible, but in the middle of the tragic news from Japan we received word of a new treatment for hepatitis C that has good prospects of increasing cure rates and avoiding side-effects so terrible many people prefer the disease. Only The Age and ABC seem to have covered it.
There’s still a way to go before the treatment’s success is confirmed, let alone it becomes widely available, but there’s a decent chance that in a couple of years doctors will use this work to save the lives of more people than died in the recent run of disasters. And the year after that, they’ll do it again, and again.
The trial was paid for by Roche, which stands to make a lot of money if its drugs work. However, it was based on early prior publicly funded research. I can say that without bothering to check, because all significant medical advances these days are utterly dependent on government-funded research at some point in their process.
That is why rumours the federal government is considering cutting $400 million over three years (about 20%) from the National Health and Medical Research Council are concerning. Unless you plan never to get sick, cuts to medical research funding affect you.
Many years ago, Science Minister Barry Jones called scientists “wimps” for not fighting for their research grants. This time something is different. The Walter and Eliza Hall Institute has kicked off a campaign called Discoveries Need Dollars, and a lot of medical scientists have got on board, using social networking, research institutes’ media advisers and human interest stories from patients who’ve had their lives saved by recent medical advances.
The campaigners have noted that it’s not as if lots of money is being thrown at bad research. About 20% of applications of NHMRC grants are successful, but review processes rate 40%-50% as definitely deserving funding, with many more worthy of serious consideration. Not every line of research will bear fruit, but some, such as the work that led to the bionic ear, the use of lithium to treat bipolar disorder and the first treatments for leukaemia, pay for themselves hundreds of times over.
An evident danger is that 20% less medical research will be done, leading to 20% fewer lifesaving findings. A less obvious risk is that efforts will be made to stretch the reduced budget further, leading to poorly conducted research. Working at Australasian Science I can’t help noticing that many of the media releases we get from New Zealand refer to research conducted using sample sizes so small the value of the data appears highly questionable. It’s not hard to imagine this is a result of the drastic de-funding of New Zealand science over the past three decades.
However, the even more disturbing side of this is what we are not hearing. Apparently, the Australian Research Council, which funds non-medical science research as well as other fields, is also in danger of major cutbacks. Yet so far there is no sign of a similar campaign mounted by other scientists.
Promoting non-medical research is certainly harder. Everyone can see how a cure for cancer is relevant to them, but the same doesn’t go for learning that fundamental constants of the universe might actually vary, or how skinks select the s-x of their offspring. Shock jocks will happily attack money spent on most areas of research, but usually spare medical science their scorn.
That’s all the more reason, however, why we need a strong campaign explaining how important research in astronomy and zoology, geology and climatology actually is. If the rumoured cutbacks to the ARC are real it’s time for scientists to start making the case.
*Stephen Luntz is the author of Forensics, Fossils and Fruitbats: A Field Guide to Australian Scientists (CSIRO Publishing 2011) and blogs on Australian and New Zealand science
Ah, the curse of a short memory. Are these rumoured cutbacks actually cutbacks, or simply the result of a ten-year funding boost coming to an scheduled end? The previous government launched a raft of funding initiatives in higher education and research, including increased funding for both the ARC and the NHMRC, in two major policy statements in 2001 and 2004. Almost all those initiatives – certainly all the major ones – are winding up this year, as they were always slated to. The current government hasn’t said much about these initiatives since it was elected, despite some quite vociferous criticisms of their structure (and inherent biases) way back when. They certainly haven’t given any indication of what would happen when the various initiatives wound up – and any campaign to maintain or increase the funding should have started at least eighteen months ago.
@Migraine
Well spotted.
Commentators might also recall Labor’s big increase of $510 million over 2009-10 to 2012-13 for block institutional research grants in the Sustainable Research Excellence in universities program to increase funding for the indirect costs of university research.
I’ve not heard anything about the >2,000 CSIRO staff who were planning industrial action for the first time in the organisation’s 80-year history on 22 March either though the action concerned pay and conditions. This high-pallutin’ country can ill-afford to have dedicated but disgruntled research scientists who may choose to skip camp to greener pastures in far-away countries.
Real scientists please sek more funding, animal experimenters please stop wasting our precious resources…”The history of cancer research has been a history of curing cancer in the mouse. We have cured mice of cancer for decades, and it simply didnât work in humans. Dr Richard Klausner, Director, National Cancer Institute, LA Times, May 6. 2007 We have learned well how to treat cancer in mice and rats but we still canât cure people. Professor Colin Garner, quoted in Accelerator MS Is a Powerful New Tool, Genetic Engineering & Biotechnology News, Vol. 27, No. 15. 2006 We do trials in people because animal models do not predict what will happen in humans. Dr Sally Burtles, Cancer Research UK, Report of the Expert Scientific Group on phase one clinical trials, following the TGN1412 clinical trial disaster. You really have to design the medicine for the species of interestâ¦You’ll find it very rare to find a medicine that will work in both⦠Patrick M. O’Connor, head of oncology research for Pfizer, quoted in The New York Times, 24 November.